In section Market Quotes

Aclaris Shares Fall 8.7% After Bosakitug Trial Misses Endpoints

Aclaris Therapeutics shares fell 8.7% to $3.58 shortly after Monday’s opening bell after the company reported that bosakitug failed to meet the primary and secondary endpoints in a Phase 2 trial for moderate-to-severe atopic dermatitis.

Aclaris Shares Fall 8.7% After Bosakitug Trial Misses Endpoints

The biopharmaceutical company said before the market opened that the trial evaluated bosakitug’s efficacy and safety in patients with the condition. The investigational therapy is being studied for various inflammatory conditions.

“We are disappointed that the Admiration trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-thymic stromal lymphopoietin monoclonal antibody alone,” Chief Executive Officer Neal Walker said. He added that the results “do not change our development priorities.”

Despite Monday’s decline, Aclaris shares were up more than 24% year to date.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!